An immunohistochemical study has been carried out to compare and contrast the cellular distribution of two different sialosylTn antigen binding monoclonal antibodies, MLS102 and B72.3, in the pancreas. MLS102 but not B72.3 monoclonal antibody binding increases with the content of the sialosyl-Tn epitopes. It was found that all 13 pancreatic cancer specimens bound both MLS102 and B72.3 monoclonal antibodies. Their cellular distribution in the cancer was virtually identical. Fifteen of 20 (75%) patients with chronic pancreatitis and five of 10 (50%) normal subjects were B72.3 positive, but MLS102 was completely negative in the latter group. Both monoclonal antibodies bound fetal pancreas diffusely. Thus, when pancreatic ductal cells have undergone malignant transformation, like the fetal pancreas, they express cell surface and secreted glycoconjugates with increased sialosyl-Tn epitopes suggesting enhanced 2-6 sialosyltransferase activity. This study shows that MLS102 is an extremely sensitive and specific tumour marker in the pancreas and that it is better than B72.3 in distinguishing pancreatic cancer from normal and chronic pancreatitis.
and B72.3 (Fig 2 (A) and (B) (Fig 3) . There was also weak B72.3 positive staining in some of the intraductal mucins (Fig 3, arrowed) . Half (five of 10) of the normal ductal tissues were also B72.3 positive but mucins were positive in only one of these (Fig 4) . The fetal pancreatic ductal tissue was positively stained by both of these monoclonal antibodies.
ACINAR TISSUES MLS 102 did not bind the normal or chronic pancreatitic acinar tissues which were positively stained by B72.3 in 50% (five of 10) of the normal control subjects and 75% (15 of 20) of the patients with chronic pancreatitis. Diffuse staining was found in the surface and the intracytoplasmic regions of five normal subjects positive for B72.3 (Fig 4) . The same pattern was observed in 13 of the 15 patients with chronic pancreatitis who were positive for B72.3 (Fig 3) gone malignant transformation suggests that there are increased STn epitopes, which probably form clusters, in the cell surface and secreted glycoconjugates in fetal and malignant pancreas suggesting the presence of enhanced 2-6 sialosyltransferase activity.
A number of blood tests have been produced to help diagnosis of pancreatic cancer.2 In particular, the CA19-9 assay which detects a mucin antigen with the sialylated Lewisa epitope has been shown to be the best serological marker and has a sensitivity for diagnosis of pancreatic cancer of 68-93%. However, false negative results are expected in patients who are Lewisa-b-, a situation which occurs in about 5% of whites. Specificity of CA19-9 radioimmunoassay is usually good, most studies reporting values of 80-93%, but raised CA19-9 values have been reported in up to 28% of patients with acute or chronic pancreatitis or benign obstructive jaundice. This specificity is therefore too low to allow its use as a screening test. ' 
